Loading...
•
Mar 31, 2021
ResMed Q3 2021 Earnings Report
ResMed's Q3 2021 earnings were announced, revealing comparable revenue but a net loss due to a tax reserve, with growth in specific segments and an optimistic outlook.
Key Takeaways
ResMed reported comparable revenue of $768.8 million, but experienced a net loss of $78.5 million, or $(0.54) per share, due to a $255 million reserve for a tax dispute with the Australian Tax Office. Excluding COVID-19 revenue from the prior year, revenue increased by 1% on a constant currency basis. Non-GAAP diluted EPS was $1.30. The company is optimistic about future growth, driven by increased awareness of respiratory health and adoption of digital health solutions.
Revenue was comparable at $768.8 million, but decreased 3% on a constant currency basis.
GAAP diluted earnings per share was $(0.54), while non-GAAP diluted earnings per share was $1.30.
A $255 million reserve was taken for a dispute with the Australian Tax Office, impacting net income.
The company sees accelerated awareness of respiratory health and growing adoption of digital health.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
ResMed anticipates accelerated growth in patient flow and ongoing progress toward improving 250 million lives in out-of-hospital healthcare by 2025.
Positive Outlook
- Accelerated awareness of the importance of respiratory health.
- Growing adoption of digital health solutions.
- Increased focus on healthcare delivered at home.
- Confidence in accelerated growth in patient flow.
- Ongoing progress toward improving 250 million lives in out-of-hospital healthcare by 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...